Ritholtz Wealth Management Sells 35,307 Shares of Takeda Pharmaceutical Co. $TAK

Ritholtz Wealth Management cut its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 59.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,852 shares of the company’s stock after selling 35,307 shares during the quarter. Ritholtz Wealth Management’s holdings in Takeda Pharmaceutical were worth $372,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. True Wealth Design LLC grew its stake in Takeda Pharmaceutical by 1,262.3% in the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock valued at $40,000 after buying an additional 2,512 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares during the last quarter. Advisory Services Network LLC acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at $74,000. Farther Finance Advisors LLC grew its stake in Takeda Pharmaceutical by 24.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company’s stock valued at $102,000 after buying an additional 1,378 shares during the last quarter. Finally, Global Trust Asset Management LLC acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at $110,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $17.79 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65. The firm has a market capitalization of $56.60 billion, a price-to-earnings ratio of 74.11 and a beta of -0.01. The company’s fifty day moving average is $18.23 and its two-hundred day moving average is $16.07. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.07). The company had revenue of $7.60 billion during the quarter, compared to analyst estimates of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 11th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating on the stock. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.